Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
sabatolimab - TIM3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04266301 STIMULUS-MDS2 (CMBG453B12301)
Myelodysplastic syndrome
Phase 3
500
Overall survival
Sabatolimab 800 mg + azacitidine 75 mg/m2
Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo
Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS)
as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Target Patients
Read-out Milestone(s)
2023
Publication
TBD
139 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation